AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00913107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegretol®
Description: The regime of prescription for Tegretol® during the clinical trials was as follows:~1. 150 mg twice daily for 10days, followed by,~2. 200 mg thrice daily for the next 10days, followed by,~3. 300 mg thrice daily for the next 10 days, followed by,~4. 300 mg four times daily for the final 10 days.
Study NCT00913107 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tegretol®
Description: The regime of prescription for Tegretol® during the clinical trials was as follows:~1. 150 mg twice daily for 10days, followed by,~2. 200 mg thrice daily for the next 10days, followed by,~3. 300 mg thrice daily for the next 10 days, followed by,~4. 300 mg four times daily for the final 10 days.
Study NCT01138683 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrafiltration
Description: Ultrafiltration through double lumen catheter, via central vein (Vena jugularis interna or Vena femoralis, 11 French, 15 cm for right jugular or 20 cm for femoralis and jugularis left-position). Based on severity of fluid overload the cardiologist determines the ultrafiltration rate. 'Multifiltrate Fresenius' (extracorporeal blood volume 72ml) in SCUF (slow continuous ultrafiltration) modus with pediatric lines (54 ml extracorporeal volume in the AV-set) and a pediatric filter (Ultraflux® AV paed, blood volume 18ml). Heparin to maintain an APTT between 65 en 85 seconds during ultrafiltration.
Study NCT01138683 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: diuretics
Description: Bumetanide continuous infusion to reach a prescribed negative fluid balance: dose adjustment according to the diuretic response.
Study NCT02004704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GZ402665
Description: Pharmaceutical form: Powder for concentrate for solution for infusion~Route of administration: intravenous infusion
Study NCT02675543 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vitreous Tamponade with Silicone Oil
Study NCT03382366 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blood sampling, risk of fall evaluation, and MR acquisition.
Description: Data will be collected on 1) bone/muscle metabolism through blood sampling, 2) risk of fall through OAK device; 3) muscle quality through MR acquisition.
Study NCT01347788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabozantinib
Description: Cabozantinib PO QD
Study NCT00505609 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Days Method
Description: The Standard Days Method is a fertility awareness-based method of family planning. Users avoid unprotected intercourse during cycle days 8 to 19. Study participants were for up to 13 cycles of method use.
Study NCT05137756 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT01158365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LACTIC ACID (Dermacid)
Description: Route of administration: local
Study NCT01158365 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LACTIC ACID (Dermacid)
Description: Route of administration: local
Study NCT01158365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycerine Vegetal Soap Granado Traditional
Description: Route of administration: local
Study NCT01158365 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycerine Vegetal Soap Granado Traditional
Description: Route of administration: local
Study NCT02619123 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tailored screening according to breast density
Description: Different interval of mammography screening according to breast density
Study NCT02619123 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Annual invitation to mammography
Description: Annual interval mammography screening according to international guidelines for women younger than 50 years old
Study NCT00479622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRU-015
Description: Arm 1 = 800 mg Arm 2 = 2000 mg
Study NCT01286038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: In Stage 1 the best dose of eltrombopag will be found to take into Stage 2, which will treat 15 participants at this dose.
Study NCT01831427 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match Andecaliximab
Description: Placebo to match andecaliximab administered by IV infusion
Study NCT04033406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-2482
Description: VIR-2482 given by intramuscular injection
Study NCT04033406 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile normal saline (0.9% NaCl) given by intramuscular injection
Study NCT03999359 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home-based Metacognitive Therapy
Description: Home-based metacognitive therapy (Home-MCT) is a facilitated self-help manual comprising six modules which participants will complete at their own pace over approximately 6 weeks. Participants will have an initial appointment with a Home-MCT trained cardiac rehabilitation staff members (face to face or by telephone). In addition, they will receive two telephone calls from trained cardiac rehabilitation staff members over the course of the intervention to offer support with completing the modules of the self-help manual.
Study NCT03984955 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sodium hyaluronate with mannitol (Ostenil Tendon)
Description: 1ml isotonic solution contains 20.0mg sodium hyaluronate and sodium chloride, disodium phosphate, sodium dihydrogen phosphate, mannitol and water for injections.
Study NCT03984955 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Platelet-Rich Plasma Injection
Description: Platelet-rich plasma (PRP) describes an autologous blood plasma fraction enriched with platelets which is then injected at the site of tendon injury.
Study NCT03984955 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Subcutaneous sham injection
Description: Sham injection will penetrate the skin, but no therapeutic substance will be injected
Study NCT04704271 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled THC
Description: 4 mg inhaled THC
Study NCT04704271 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhaled placebo (no active cannabinoids)
Study NCT03442088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: Apremilast will be given as approved by the FDA for the treatment of moderate to severe plaque psoriasis. An initial dosage titration from Day 1 (10mg) to Day 5 (30mg). Following the titration, the recommended maintenance dosage of 30 mg twice daily taken orally starting on Day 6 will be dispensed, as per labeled indication.
Study NCT04221360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-375
Description: Test drug, QD, PO
Study NCT04221360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D390
Description: Reference drug, QD, PO
Study NCT05781022 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic repair of iatrogenic esophageal perforation
Description: For patients in EG, we began with assessment of the site \& size of perforation . In this study, In this study, we used a fully covered stent (Mega stent, Taewoong Medical Industries, Gyeonggi-do, South Korea) ultra large and long (length: 24 cm, diameter: 36 mm) stent. We did not experience any complication with Mega stent, particularly migration, thanks to the design of Mega stent that fits well for the post-sleeve anatomy with reduction of migration.~Concurrently, the interventional radiology team subcutaneously drained the intraperitoneal free fluid using 2 intra-peritoneal tubes that were placed under US guidance in the sub-hepatic region and in the pelvis
Study NCT02187003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivipansel
Description: Rivipansel (GMI-1070) will be infused intravenously every 12 hours up to 15 doses maximum. Subjects aged 12 and over who weigh more than 40 kilograms will receive a dose of 1680 mg of rivipansel, followed by a dose of 840 mg of rivipansel every 12 hours. All subjects aged 6 to 11 years and any subject who weighs 40 kilograms or less, will receive weight-based dosing (mg/kg) of 40 mg/kg of rivipansel (maximum of 1680 mg) followed by a dose of 20 mg/kg of rivipansel (maximum of 840 mg) every 12 hours.
Study NCT02187003 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (phosphate buffered saline) will be infused intravenously every 12 hours up to 15 doses maximum.
Study NCT02460432 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting metal Stent
Description: Insertion of Niti-S Mira-Cover III Biliary Stent using ERCP
Study NCT02460432 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Covered Metal Stent
Description: Insertion of ComVi Biliary Covered Stent using ERCP
Study NCT05128266 — intervention group
Intervention type: PROCEDURE
Intervention: Endodontical Retreatment
Description: 1. Linear canal Removal of the coronal dentine in order to create the space useful to an extractor to catch and remove the instrument. The preferred instrument to reach this aim is a .15 or .20 ultrasonic tip.~2. Curve canal When the instrument is broken inside a curve canal, it is not possible to create a circumferential space around the separated instrument without the risk of root perforation. Thus, the first step is the removal of the dentine of the external wall of the root canal. The second step is the removal of the dentine of the internal wall of the root canal. This selective removal of dentinal tissue unlocks thee separated instrument and determines its mobilization. Thus, the irrigation itself makes the instrument available for the removal.~After the removal of the broken instrument, root canal preparation was completed Canal filling was performed based on Schilder's technique.
Study NCT00028262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cystagon
Study NCT01979523 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01979523 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01979523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given PO
Study NCT04137107 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04137107 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT01979523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uprosertib
Description: Given PO
Study NCT01038102 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PUFA Diet
Description: Diet high in polyunsaturated (rich in linoleic acid, omega-6) fat (15 E%).
Study NCT01038102 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SFA diet
Description: Diet high in saturated fat (15E%)
Study NCT02807831 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Executive functions training
Description: Daily training of executive functions via activities to develop auto-regulation, attention and memory.
Study NCT02807831 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Language skills training
Description: Daily training of language skills via activities to develop phonological awareness and vocabulary.
Study NCT02807831 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regular school curriculum
Description: Ministry of Education national school curriculum.
Study NCT01901042 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Symbiotic
Description: Sachets with a symbiotic product in powder form containing 4.3 g of dietary fiber and Lactobacillus reuteri in a concentration greater than 1.0 x 108 colony forming units (CFU), with five grams per sachet (Fibermais Flora Nestlé Brazil).
Study NCT01901042 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Control patients will receive sachets containing maltodextrin
Study NCT03602716 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HD-tDCS
Description: HD-tDCS is going to be delivered at 1.5 mA intensity for 20 minutes once a day (+15 s fade-in and fade-out); sessions will be performed on 10 days 5 consecutive weekdays with sustained effects at T1 and T2. HD-tDCS will be used with the anode placed over the left DLPFC (F3) surrounded by four cathodes at F5, F1, FC3, and AF3 based on the 10/20 international EEG system.
Study NCT03602716 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham HD-tDCS
Description: HD-tDCS is going to be used with the anode placed over the left DLPFC (F3) surrounded by four cathodes at F5, F1, FC3, and AF3 based on the 10/20 international EEG system; sessions will be performed on 10 days 5 consecutive weekdays with sustained effects at T1 and T2. This group will have a 20-min-sham stimulation.
Study NCT00503347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bavituximab
Description: The study drug is a sterile solution administered intravenously weekly for 8 weeks. Each cohort is given 0.3, 1, 3, or 6 mg/kg of bavituximab.
Study NCT00459719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus modified-release
Description: oral
Study NCT00459719 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prograf
Description: oral
Study NCT04192890 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Focal irreversible electroporation of the prostate cancer
Description: Irreversible electroporation is a non-thermal tissue ablation technique in which short duration electrical fields are used to permanently permeabilize the cell membrane.
Study NCT03621436 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TRVD Therapy
Description: A catheter-mounted expandable flow pump is to be deployed in a transfemoral venous catheterization procedure. Once in place, renal venous pressure is reduced to a pre-selected physiologic target pressure and kept there for up to 24 hours. After termination of TRVD therapy, the device is removed.
Study NCT02591641 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anti-shear mattress overlay
Description: A commercial full-length LiquiCell® anti-shear mattress overlay (ASMO) was placed on the standard ambulance stretcher mattress.
Study NCT02591641 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard ambulance stretcher mattress
Study NCT04137107 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Given PO
Study NCT04137107 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO
Study NCT02185560 — intervention group
Intervention type: DRUG
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: Patients treated by Physician with Nexavar under approved local prescriptions
Study NCT03366116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aza-TdC
Description: Methylation-mediated silencing of genes is an epigenetic mechanism implicated in carcinogenesis; agents that inhibit this mechanism are of clinical interest because of their potential to re-activate silenced tumor suppressor genes. The nucleoside analog 5-aza-4'-thio-2'- deoxycytidine (Aza-TdC) is incorporated into DNA, where it engages the active site of DNA methyltransferase I (DNMT1), a maintenance methyltransferase that contributes to hypermethylation and silencing of tumor suppressor genes. Aza-TdC offers an improvement over traditional DNMT inhibitors via higher incorporation into DNA and lower cytotoxicity; Aza-TdC has greater antitumor activity than another recently developed DNMT1 inhibitor, TdCyd, in some solid tumor xenograft models. Treatment with Aza-TdC is anticipated to yield inhibition of tumor growth due to DNMT1 depletion at oral doses that are well tolerated in extended dosing schedules.
Study NCT00324805 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study NCT00324805 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV
Study NCT00324805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT00324805 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Given IV
Study NCT00324805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV
Study NCT00324805 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine Hydrochloride
Description: Given IV
Study NCT00324805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV
Study NCT00324805 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00324805 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00324805 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed Disodium
Description: Given IV
Study NCT00324805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed Disodium
Description: Given IV
Study NCT04351009 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sentinel lymph node mapping
Description: Through on-table colonoscopy indocyanine green solution will be injected in the submucosa at 2-4 points around the tumor for laparoscopic surgeries. Dye will be injected in the subserosa at 2-4 points for open surgeries. Lymphatic flow from the tumor will be mapped in real time with near-infrared fluorescence imaging scope and sentinel lymph nodes will be identified.
Study NCT02105376 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trigeminal Nerve Stimulation (TNS)
Description: Trigeminal Nerve Stimulation (TNS)
Study NCT03122002 — intervention group
Intervention type: DRUG
Intervention: Drug Therapy
Description: For this observation research, anti platelet drugs, statins and ect. would be used as clinical guidelines as usal, and statical ananysis of the relationship between these drugs and the final outcomes
Study NCT03122002 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Routine Blood Test and Image Scan
Description: Routine blood test(HCY, LDL and ect.) and image scan (DWI, DSA and ect.)
Study NCT03122002 — intervention group
Intervention type: OTHER
Intervention: Intravascular therapy
Description: Intravascular therapy including thrombectomy
Study NCT03122002 — intervention group
Intervention type: OTHER
Intervention: Emergency Treatment
Description: Emergency treatment including time to self-diagnosis of stroke, time to call for help, devices used to hospital and ect.
Study NCT03122002 — intervention group
Intervention type: OTHER
Intervention: Medical history
Description: Medical history including hypertension, diabetes, hyperlipemia and ect.
Study NCT00324805 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT00324805 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT00324805 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine Tartrate
Description: Given IV
Study NCT00324805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine Tartrate
Description: Given IV
Study NCT04275713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin is an oral antidiabetic drug
Study NCT04275713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 40 mg/m2 given intravenously once a week, maximum 6 cycles
Study NCT04275713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 40 mg/m2 given intravenously once a week, maximum 6 cycles
Study NCT04489238 — intervention group
Intervention type: OTHER
Intervention: Risk Factor Questionnaire
Description: Participants, both cases and controls, will complete the CYOC risk factor questionnaire, preferably at the time of first visit
Study NCT06312436 — intervention group
Intervention type: PROCEDURE
Intervention: Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA)
Description: Temporary aortic occlusion can limit haemorrhage, can help to maintain perfusion to the heart and brain, and may be associated with improved survival.
Study NCT04427384 — intervention group
Intervention type: DEVICE
Intervention: GammaTile
Description: Surgically Targeted Radiation Therapy
Study NCT03212170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]Fluorofuranylnorprogesterone (FFNP) PET/MR Imaging
Description: 18F-Fluorofuranylnorprogesterone (FFNP) PET/MR Imaging tracer
Study NCT06075979 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumbar disc herniation
Description: Patients undergoing surgery for lumbar disc herniation
Study NCT06075979 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumbar spinal stenosis
Description: Patients undergoing surgery for lumbar spinal stenosis
Study NCT05815953 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polarstem
Description: Stem used in total hip replacement. Manufacturer: Smith \& Nephew Orthopaedics AG, Baar, Switzerland.
Study NCT05815953 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Corail
Description: Stem used in total hip replacement. Manufacturer: De Puy Int Ltd, Leeds, UK.